Sonnet BioTherapeutics Holdings is a clinical-stage biopharmaceutical company with a proprietary technology for developing biologic medicines it refers to as FHAB (Fully Human Albumin Binding). Co. has a pipeline of therapeutic compounds focused primarily on oncology indications of unmet medical need, including SON-080, a low-dose formulation of Interleukin 6 which is in development for Chemotherapy Induced Peripheral Neuropathy; SON-1010, which is being developed for solid tumor indications, including non-small cell lung cancer and head and neck cancer, as well as for antiviral applications; and SON-1210, which is being developed for solid tumor indications, including colorectal cancer.